Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate)

The combination delivers levodopa, a dopamine precursor, while carbidopa blocks its peripheral conversion, increasing brain availability. Entacapone inhibits the COMT enzyme, slowing levodopa breakdown. Together they enhance and prolong dopaminergic stimulation in the central nervous system.

Dosing is individualized and determined by the prescribing clinician based on disease severity, patient response, and tolerability. The prescriber will adjust the amount and frequency to achieve optimal motor control while minimizing side effects.

Safety data in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the Lecigimon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lecigimon adds entacapone to the traditional levodopa/carbidopa regimen, which reduces peripheral levodopa metabolism and extends its half‑life. This often results in smoother motor control and fewer OFF periods compared with levodopa/carbidopa alone, though individual response may vary.

Lecigimon tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability.

The medication is taken orally, usually with food or a light snack to reduce gastrointestinal irritation. Tablets are swallowed whole with water; they should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include the development of dyskinesia (involuntary movements), psychiatric effects such as hallucinations or severe confusion, and rare but significant liver enzyme elevations. Patients should be monitored regularly for these events, and therapy should be adjusted or discontinued if they occur.

Lecigimon is contraindicated in patients with known hypersensitivity to any component, those currently taking non‑selective MAO inhibitors, or individuals with severe hepatic impairment. Caution is also advised for patients with a history of cardiac arrhythmias or uncontrolled hypertension.